Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Current Value
$742.191 Year Return
Current Value
$742.191 Year Return
Market Cap
$81.82B
P/E Ratio
18.43
1Y Stock Return
-6.79%
1Y Revenue Growth
5.72%
Dividend Yield
0.00%
Price to Book
2.8
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
XYL | 44.33% | $29.70B | +21.00% | 1.15% |
SN | 41.26% | $13.84B | +118.64% | 0.00% |
IDYA | 40.28% | $2.24B | -15.21% | 0.00% |
HII | 40.09% | $7.50B | -19.92% | 2.70% |
RCKY | 39.59% | $155.86M | -17.74% | 2.95% |
APTV | 39.28% | $12.25B | -35.53% | 0.00% |
ANIK | 39.21% | $249.56M | -17.52% | 0.00% |
SRI | 39.15% | $166.13M | -63.46% | 0.00% |
ARW | 39.01% | $5.98B | -5.69% | 0.00% |
ICE | 38.87% | $90.68B | +39.21% | 1.12% |
NSIT | 37.99% | $4.75B | -0.16% | 0.00% |
SPXC | 37.43% | $7.79B | +95.19% | 0.00% |
BIIB | 36.99% | $22.65B | -32.30% | 0.00% |
MG | 36.47% | $282.81M | +42.06% | 0.00% |
JAZZ | 36.39% | $7.06B | -1.23% | 0.00% |
SNN | 35.74% | $11.12B | -0.04% | 2.98% |
IDXX | 35.46% | $34.09B | -12.85% | 0.00% |
TFX | 35.26% | $8.97B | -10.85% | 0.71% |
PSMT | 34.86% | $2.70B | +32.81% | 1.34% |
IQV | 34.74% | $34.73B | -7.77% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CMTL | -0.04% | $84.44M | -76.16% | 0.00% |
ALLT | -0.13% | $149.73M | +186.40% | 0.00% |
OOMA | 0.14% | $365.28M | +16.00% | 0.00% |
BMBL | -0.16% | $845.98M | -43.90% | 0.00% |
CRCT | 0.25% | $1.12B | -19.90% | 1.91% |
ARQ | -0.26% | $332.89M | +216.80% | 0.00% |
FATBB | 0.38% | $81.94M | -12.91% | 11.69% |
X | 0.46% | $8.76B | +13.32% | 0.51% |
TPST | 0.53% | $37.75M | -77.59% | 0.00% |
WWW | 0.55% | $1.79B | +171.57% | 1.80% |
UFI | -0.58% | $102.66M | -11.22% | 0.00% |
SCWX | 0.59% | $743.12M | +40.27% | 0.00% |
BALY | 0.64% | $726.31M | +54.50% | 0.00% |
RYI | -0.68% | $751.91M | -19.47% | 3.18% |
ORKA | 0.74% | $780.47M | +82.82% | 0.00% |
AGX | 0.89% | $2.01B | +224.91% | 0.85% |
ALTG | 0.96% | $236.78M | -29.08% | 3.22% |
RGR | -0.99% | $642.75M | -15.87% | 1.81% |
CORZ | -1.00% | $4.60B | +3,201.26% | 0.00% |
DXCM | 1.06% | $29.25B | -31.28% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UUU | -30.01% | $4.97M | -41.89% | 0.00% |
ROOT | -23.34% | $1.53B | +972.93% | 0.00% |
HUSA | -21.49% | $16.69M | -11.56% | 0.00% |
PAYC | -20.33% | $12.12B | +21.78% | 0.69% |
SXC | -19.10% | $1.05B | +39.93% | 3.52% |
ETR | -16.43% | $32.14B | +49.00% | 3.05% |
ATEC | -14.79% | $1.36B | -16.49% | 0.00% |
TK | -13.08% | $728.26M | +11.06% | 0.00% |
COP | -12.28% | $130.16B | -1.63% | 2.59% |
LNG | -12.23% | $49.37B | +24.99% | 0.82% |
FSLY | -11.48% | $941.41M | -61.50% | 0.00% |
FDP | -11.13% | $1.62B | +45.67% | 2.97% |
PULM | -10.86% | $19.83M | +202.98% | 0.00% |
CFLT | -10.66% | $9.28B | +49.05% | 0.00% |
LPLA | -10.58% | $23.55B | +38.13% | 0.38% |
MATX | -10.14% | $5.07B | +59.09% | 0.86% |
AME | -10.02% | $44.75B | +24.49% | 0.56% |
SOC | -9.95% | $1.93B | +74.70% | 0.00% |
CBOE | -9.33% | $21.46B | +15.84% | 1.11% |
FPI | -9.24% | $600.71M | +2.46% | 1.94% |
Yahoo
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […]
MarketWatch
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
SeekingAlpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ETCompany ParticipantsRyan Crowe - SVP,...
SeekingAlpha
Regeneron's stock drop presents a buying opportunity amidst regulatory and market uncertainty. Click here to read an analysis of REGN stock now.
Yahoo
Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund was down 3.72% for the quarter vs. +2.54% for the MSCI ACWI (in $A). It was down 5.59% in September vs. -0.35% for the index. The market rose in the […]
SeekingAlpha
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GBIL | -0.09% | $5.60B | 0.12% |
IBDP | 0.37% | $2.11B | 0.1% |
KCCA | -0.40% | $220.51M | 0.87% |
YEAR | -0.54% | $1.13B | 0.25% |
BUXX | -1.00% | $162.67M | 0.25% |
AGZD | -1.05% | $142.76M | 0.23% |
DBB | 1.18% | $126.37M | 0.77% |
IBTE | 1.23% | $1.70B | 0.07% |
UNG | 1.32% | $908.80M | 1.06% |
XHLF | 1.89% | $874.27M | 0.03% |
USCI | -2.14% | $185.47M | 1.07% |
MINT | 2.15% | $11.62B | 0.35% |
CMDY | -2.47% | $279.14M | 0.28% |
FTGC | -2.70% | $2.17B | 1.02% |
DBMF | 2.73% | $1.02B | 0.85% |
XONE | 2.73% | $548.88M | 0.03% |
IVOL | -2.79% | $548.70M | 1.02% |
GCC | -2.86% | $133.23M | 0.55% |
BCI | -2.87% | $1.20B | 0.26% |
ICLO | 2.94% | $209.30M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -28.21% | $195.31M | 0.85% |
UUP | -17.25% | $309.25M | 0.77% |
USDU | -16.17% | $201.97M | 0.5% |
TAIL | -15.31% | $67.98M | 0.59% |
BTAL | -15.30% | $388.04M | 1.43% |
DBE | -13.34% | $50.13M | 0.77% |
TPMN | -13.26% | $40.60M | 0.65% |
DBO | -11.87% | $217.57M | 0.77% |
GSG | -11.43% | $914.42M | 0.75% |
COMT | -11.37% | $829.06M | 0.48% |
CORN | -10.84% | $61.12M | 0.2% |
CTA | -10.47% | $350.27M | 0.78% |
KMLM | -9.64% | $353.87M | 0.9% |
JBBB | -9.32% | $1.26B | 0.49% |
HDRO | -7.68% | $164.26M | 0.3% |
WEAT | -7.29% | $120.27M | 0.28% |
SOYB | -5.39% | $27.32M | 0.22% |
DBA | -4.73% | $755.88M | 0.93% |
PDBC | -4.64% | $4.40B | 0.59% |
DBC | -4.32% | $1.39B | 0.87% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 58.53% | $397.87M | 0.35% |
IBB | 56.77% | $6.66B | 0.45% |
VHT | 55.89% | $17.06B | 0.1% |
IYH | 55.61% | $3.19B | 0.39% |
FHLC | 55.38% | $2.73B | 0.084% |
XLV | 54.00% | $38.41B | 0.09% |
IXJ | 53.80% | $3.89B | 0.41% |
FXH | 52.21% | $1.15B | 0.62% |
PBE | 52.06% | $258.53M | 0.58% |
PPH | 49.16% | $592.06M | 0.36% |
PINK | 49.05% | $161.15M | 0.5% |
RSPH | 48.92% | $885.96M | 0.4% |
IHE | 48.64% | $596.23M | 0.39% |
FBT | 48.26% | $1.11B | 0.56% |
FDLO | 47.38% | $1.27B | 0.15% |
ACWV | 46.75% | $4.24B | 0.2% |
FTCS | 46.69% | $8.97B | 0.54% |
USMV | 46.22% | $23.89B | 0.15% |
DGRW | 45.14% | $14.87B | 0.28% |
GLOV | 45.07% | $1.04B | 0.25% |